Geneva, Oct. 15 -- International Clinical Trials Registry received information related to the study (ChiCTR2600134174) titled 'Retrospective analysis of the efficacy and safety of 100 mg abrocitinib in patients with moderate to severe atopic dermatitis: Real-world study' on Oct. 12.
Study Type: Observational study
Study Design:
Cohort study
Primary Sponsor: Shenzhen Second People's Hospital
Condition:
Atopic dermatitis
Intervention:
Group A: ABRO-naive Group :N/A
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2022-07-01
Target Sample Size: Group A: ABRO-naive Group :168;Group D: DUPI-switch Group:96;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?p...